Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | CYP4Z1 | Q86W10 | 2/20 | 0.40 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.40 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2037474 | 0.80 | LTB4R (0.48) | SMN1; SMN2ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL6976089 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1TSHRPOLBL3MBTL1 | |
| SCHEMBL10695926 | 0.79 | DAO (0.39) | SMN1; SMN2ALDH1A1TSHRDAO | |
| SCHEMBL3939509 | 0.76 | RPS6KB2 (0.42) | KAT2BALDH1A1TSHRHSD17B10L3MBTL1 | |
| SCHEMBL6643050 | 0.75 | SMN1; SMN2 (0.63) | CYP1A2CYP4F2CYP4A11CYP3A4SMN1; SMN2 | |
| SCHEMBL7354171 | 0.73 | IAPP (0.41) | SMN1; SMN2ALDH1A1L3MBTL1DAO | |
| SCHEMBL14280335 | 0.73 | CYP4F2 (0.47) | CYP1A2CYP4F2CYP4A11CYP3A4SMN1; SMN2 | |
| SCHEMBL8855371 | 0.73 | DAO (0.42) | CYP1A2CYP3A4SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL8588999 | 0.72 | DAO (0.32) | DAO | |
| SCHEMBL8540112 | 0.71 | DAO (0.41) | SMN1; SMN2ALDH1A1TSHRDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034093-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20240358675-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| CN-118165002-A | Polycyclic compounds and methods of use thereof | 桑诺维恩药品公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-3252057-B1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-20200323819-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2020-10-15 | — | — | US | disclosed |
| US-20200323819-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2020-10-15 | — | — | US | disclosed |
| US-20140256712-A1 | Multicyclic Compounds and Methods of Use Thereof | PSYCHOGENICS INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-8710245-B2 | Multicyclic compounds and methods of use thereof | PSYCHOGENICS INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710245-B2 | Multicyclic compounds and methods of use thereof | PSYCHOGENICS INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710245-B2 | Multicyclic compounds and methods of use thereof | PSYCHOGENICS INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PSYCHOGENICS INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PSYCHOGENICS INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PSYCHOGENICS INC. (US) | 2013-05-02 | — | — | US | disclosed |
| EP-2507245-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011069063-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011069063-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | CYP1A2 411/4885CYP4F2 488/4885CYP4A11 490/4885 |
| US-20200323819-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | CYP1A2 411/4885CYP4F2 488/4885CYP4A11 490/4885 |
| US-20240358675-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | CYP1A2 411/4885CYP4F2 488/4885CYP4A11 490/4885 |
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | GRIN2C, NLN, COMT | CYP1A2 411/4885CYP4F2 488/4885CYP4A11 490/4885 |
| US-20140256712-A1 | Multicyclic Compounds and Methods of Use Thereof | GRIN2C, NLN, COMT | CYP1A2 411/4885CYP4F2 488/4885CYP4A11 490/4885 |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | CYP1A2 411/4885CYP4F2 488/4885CYP4A11 490/4885 |
| US-20260034093-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SLC6A3, SLC6A11, SLC6A13 | CYP1A2 490/4885CYP4F2 906/4885CYP4A11 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.